• Less than 30 years of age at diagnosis of neuroblastoma
• End of Induction disease evaluation showing complete, partial, mixed response, or stable disease
• Hematopoietic recovery from last induction chemotherapy course
• No uncontrolled infection
• Minimum frozen PBSCs of 2 x 10^6 CD34 cells/kg for each transplant; 2 x 10^6 CD34 cells/kg for back-up strongly recommended; total at least 6 x 10^6 CD34 cells/kg collected before consolidation
• Adequate organ function: hepatic (AST and ALT < 3x upper limit normal; total bilirubin ≤1.5x ULN if baseline normal), cardiac (shortening fraction ≥27% or ejection fraction ≥45%, no heart failure), pulmonary (no dyspnea at rest, no oxygen needed), renal (creatinine clearance or GFR > 60 mL/min/1.73m²)
• Recovery from acute toxicities of last induction chemotherapy
• Appropriate written consent from adult or parent/guardian if patient is under 18, and minor information sheet if patient is over 8 years old

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety